Bob Ingram is Vice Chairman Pharmaceuticals, GlaxoSmithKline and a special consultant to the CET and the Group.
Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-lead the merger and integration that formed GlaxoSmithKline, the world's second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, he was asked by the Board to serve as Vice Chairman Pharmaceuticals, GSK.
Bob serves as Chairman, OSI Pharmaceuticals, Inc. and Chairman, VALEANT Pharmaceuticals International. He also serves on the Board of Directors of Allergan Inc., Edwards Lifesciences Corporation, Lowe's Companies, Inc., and the Wachovia Corporation.
He is Vice Chairman, American Cancer Society Foundation; Founder of CEO Roundtable on Cancer; Chairman of American Foundation for Pharmaceutical Education; and member of the Boards for Business Higher Education Forum, James B. Hunt Jr. Institute for Educational Leadership and Policy, Project HOPE, Research Triangle Foundation of North Carolina and member of National Board for Professional Teaching Standards President's Roundtable. On 27 July 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.
Bob graduated from Eastern Illinois University with a BS degree in Business Administration.
